In B-cell lymphoma, DNA hypermethylation in the promoter region of Spry2 (a negative regulator of ERK signaling) results in its transcriptional silencing, thereby relieving inhibition of the MAPK-ERK pathway and enhancing cell proliferation and survival (Frank et al., 2009[32]). The gene discussed is MAPK1; the disease is B-cell non-Hodgkin lymphoma.